Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab

BACKGROUND: We evaluated shedding of epidermal growth factor type II receptor (Her2/neu) extracellular domain (ECD) in primary uterine serous carcinoma (USC) cell lines and in the serum of USC patients and its biological effects in experiments of trastuzumab-induced cytotoxicity in vitro. METHODS: H...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Todeschini, P, Cocco, E, Bellone, S, Varughese, J, Lin, K, Carrara, L, Guzzo, F, Buza, N, Hui, P, Silasi, D-A, Ratner, E, Azodi, M, Schwartz, P E, Rutherford, T J, Pecorelli, S, Santin, A D
Formato: Artigo
Lenguaje:Inglês
Publicado: Nature Publishing Group 2011
Materias:
Translational Therapeutics
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3208497/
https://ncbi.nlm.nih.gov/pubmed/21915118
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2011.369
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares